Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839982 · ClinicalTrials.gov registry record · Phase 1
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00839982 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 35 participants.
The verdict
NCT00839982, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase I/II trial studied the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have relapsed or not responded to treatment.
Interventions
- DRUG clofarabine
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839982
The ClinicalTrials.gov registry entry for NCT00839982 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clofarabine is the first listed.
NCT00839982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839982 about?
NCT00839982 is a clinical study titled "Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS". This phase I/II trial studied the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have relapsed or not responded to treatment.
What is the current status of trial NCT00839982?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00839982?
The interventions under investigation include: clofarabine (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00839982?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.